Author:
Modi N.D.,Danell N.O.,Perry R.N.A.,Abuhelwa A.Y.,Rathod A.,Badaoui S.,McKinnon R.A.,Haseloff M.,Shahnam A.,Swain S.M.,Welslau M.,Sorich M.J.,Hopkins A.M.
Funder
Cancer Council South Australia
National Breast Cancer Foundation
National Health and Medical Research Council
Reference42 articles.
1. HER2-positive advanced breast cancer treatment in 2020;Cesca;Cancer Treat Rev,2020
2. Current and future management of HER2-positive metastatic breast cancer;Martínez-Sáez;JCO Oncol Pract,2021
3. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Eng J Med,2005
4. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study;Swain;Lancet Oncol,2013
5. Trastuzumab emtansine for HER2-positive advanced breast cancer;Verma;N Eng J Med,2012